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Abstract
Investigators have linked rare copy number variation (CNVs) to neuropsychiatric diseases, such as schizophrenia. One
hypothesis is that CNV events cause disease by affecting genes with specific brain functions. Under these circumstances, we
expect that CNV events in cases should impact brain-function genes more frequently than those events in controls. Previous
publications have applied ‘‘pathway’’ analyses to genes within neuropsychiatric case CNVs to show enrichment for brain-
functions. While such analyses have been suggestive, they often have not rigorously compared the rates of CNVs impacting
genes with brain function in cases to controls, and therefore do not address important confounders such as the large size of
brain genes and overall differences in rates and sizes of CNVs. To demonstrate the potential impact of confounders, we
genotyped rare CNV events in 2,415 unaffected controls with Affymetrix 6.0; we then applied standard pathway analyses
using four sets of brain-function genes and observed an apparently highly significant enrichment for each set. The
enrichment is simply driven by the large size of brain-function genes. Instead, we propose a case-control statistical test, cnv-
enrichment-test, to compare the rate of CNVs impacting specific gene sets in cases versus controls. With simulations, we
demonstrate that cnv-enrichment-test is robust to case-control differences in CNV size, CNV rate, and systematic differences
in gene size. Finally, we apply cnv-enrichment-test to rare CNV events published by the International Schizophrenia
Consortium (ISC). This approach reveals nominal evidence of case-association in neuronal-activity and the learning gene sets,
but not the other two examined gene sets. The neuronal-activity genes have been associated in a separate set of
schizophrenia cases and controls; however, testing in independent samples is necessary to definitively confirm this
association. Our method is implemented in the PLINK software package.
Citation: Raychaudhuri S, Korn JM, McCarroll SA, The International Schizophrenia Consortium, Altshuler D, et al. (2010) Accurately Assessing the Risk of
Schizophrenia Conferred by Rare Copy-Number Variation Affecting Genes with Brain Function. PLoS Genet 6(9): e1001097. doi:10.1371/journal.pgen.1001097
Editor: David B. Allison, University of Alabama at Birmingham, United States of America
Received March 11, 2010; Accepted July 27, 2010; Published September 9, 2010
Copyright:  2010 Raychaudhuri et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: For this work, SR is supported by a K08 National Institutes of Health (NIH) career development award (AR055688). MJD is supported by NIH grants
through the U01 (HG004171, DK62432) and R01 (DK083756-1, DK64869) mechanisms. The MIGen study was funded by funding from the NIH-NLBI (R01HL087676)
and a grant from the National Center for Research Resources. The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: mjdaly@chgr.mgh.harvard.edu (MJD); shaun@pngu.mgh.harvard.edu (SP)
" Please see Acknowledgements for consortium authorship.
Introduction
Multiple recent studies have demonstrated a convincing and
statistically significant excess of rare CNVs in individuals affected
by schizophrenia compared to unaffected individuals [1–4].
Similar observations have now been made separately in autism
[5–7] and bipolar disorder [8]. However, it is typically not readily
evident which individual CNV events are pathogenic since (1)
many rare events are seen in the general population and the excess
in cases is relatively modest and (2) individual events are too rare
to demonstrate definitive association in realistically sized patient
collections. Hence, it is challenging to translate these rare CNV
events into a clear understanding of disease pathology. To identify
candidate genes for follow-up, investigators have employed
statistical tests of gene set enrichment, originally developed as an
effective approach to interpret gene expression data [9].
Practically, these analyses identify functional gene sets or
‘pathways’ that are over-represented among those genes affected
by case CNVs compared to unaffected genes [1,8,10,11], often
relying on online resources such as Panther [12], Ingenuity
Pathway Analysis (Ingenuity Systems, www.ingenuity.com), and
Gene Ontology [13].
For example, gene set enrichment analyses by Walsh et al.
suggested that rare CNVs in schizophrenia preferentially disrupt
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those genes with neuro-developmental functions [1]; Zhang et al.
similarly reported that rare CNVs in bipolar disorder preferen-
tially overlap genes involved in behavior and learning [8]. More
recently Glessner et al. reported that genes affected by rare and
common CNVs in autism are also involved in brain function [11].
While these initial results are highly promising, the gene set
enrichment statistical framework as applied to copy number
variation is critically limited and potentially confounded.
The key analytical question in this setting is whether an event
that impacts a set of genes or a pathway, increases disease risk
compared to events that do not impact that pathway. Under the
hypothesis that events affecting a specific brain-function
pathway are pathogenic, the rate of those events affecting the
brain-function pathway should indeed be greater in cases than
in controls – ideally fully explaining the observed genome-wide
differences in case and control event rates. An alternative
possibility is that the increased rate and size of CNVs in cases
represents a mutational syndrome or genomic instability, and
that they are not in themselves pathogenic. Under that
possibility, case events should not preferentially impact any
particular gene set; however, differences is size and rate might
be observed.
The commonly used gene set enrichment analytical approach
used to address this question falls short on two accounts: (1) they
do not rigorously compare case event rates to control event rates
and (2) since they examine affected genes rather than events, they
do not accurately account for the fact that multiple genes might be
contributed from a single event or that single genes may be
affected by multiple events. Here we propose a straight forward
statistical test to explicitly compare the rate of CNVs impacting a
specific gene set in cases to the rate in controls that carefully
accounts for background differences in CNV rate and size.
A possible consequence of not rigorously comparing event rates
in cases to controls is that sets consisting of genes that are more
frequently affected by CNVs might spuriously appear to be highly
enriched in cases, but also will be highly enriched in controls.
Examples of such genes include large genes spanning a massive
portion of the genome or those whose functions are highly
redundant or non-essential. This is a particularly important issue
for neuropsychiatric disease considering the reportedly large size of
genes with brain function. Multiple studies of CNVs in the general
population have reported enrichment for neuro-physiological genes
[14,15] – suggesting that brain-function genes may be susceptible to
CNV events in general, possibly due to their large size or other
factors. In fact, published events in neuropsychiatric disease studies
often implicate large genes (see Table S1). Others have already
noted that gene size itself can bias pathway enrichment analyses in
other contexts, such as annotating non-coding elements for function
[16,17]. In particular, Taher et al noted that randomly selected
positions in the genome are enriched for proximity to genes involved
in ‘‘development’’, ‘‘cell-adhesion’’, and ‘‘nervous system develop-
ment’’ [17]. Some of the published disease studies attempted to
address this issue indirectly by applying similar analyses to control
events and note the lack of statistical evidence of enrichment for
brain function gene sets [1,8]; however, control events are typically
fewer and smaller, implicating many fewer genes, and therefore
simply comparing the statistical significance of gene set enrichment
results in cases and controls is not adequate.
One possible consequence of examining genes rather than the
events they occur in is that individual large events contribute many
genes and may skew the analysis much more than smaller events,
and cause spurious findings. This is of particular concern since
genes with common function can often cluster together on the
genome and a single event in one individual affecting a cluster of
related genes can naively appear to implicate an entire pathway
[18,19]. One interesting example is the reported enrichment of
psychological disorder genes in the Zhang et al data set (see Table S1);
11 of the 16 deleted psychological disorder genes are in the 22q11.21
region observed in two individuals in the data set [8]. These genes
are possibly annotated as psychological disorder genes since rare
deletions in 22q11.21 have long been observed among schizo-
phrenia cases [2]. Removal of the two individuals with 22q11.21
events eliminates any enrichment for the psychological disorder gene
set – suggesting that there is little evidence that this particular set is
necessarily relevant to disease outside of the 22q11.21 region. Of
course at least one gene in this region is pathogenic, but it is
unlikely that .10 in this region are and that in aggregate define a
key pathogenic set.
A second possible consequence of examining genes and not the
events they occur in is that genes affected in both cases and
controls, but at different rates, are not properly accounted for. For
instance, a critical gene affected by many pathogenic events
contributes equally to a gene set enrichment analyses as a gene
sporadically affected by a single event. One interesting example is
the NRXN1 gene, a large gene that plays an important role in
synaptic development [20]. Since CNV events affecting NRXN1
have been observed in both schizophrenic cases and controls, they
would contribute equally to a pathway analysis of case events as
they would to one of control events. However, the rate of
functional events observed in cases is significantly more than in
controls; pathway-based approaches could be bolstered if methods
explicitly take into account these differences between cases and
controls event rates for genes of interest.
Here, we describe a case-control statistical test, cnv-enrichment-test,
to explicitly compare the rate of CNVs impacting specific genes
sets in cases to controls. We show how cnv-enrichment-test is robust to
even extreme biases in gene size and case-control differences in
CNV rate and size. We also demonstrate how standard gene set
enrichment approaches is often confounded under realistic
scenarios, by gene size and other gene structural features; we
demonstrate these confounders in a set of 2,415 controls
genotyped for rare single-event deletions. We finally apply the
cnv-enrichment-test to examine genes with brain function within a
large dataset of CNVs identified in schizophrenia cases and
controls published by the International Schizophrenia Consortium
(ISC) [2] and demonstrate nominal evidence of association for
previously described gene sets.
Author Summary
Specific rare deletion and duplication events in the genome
have now been shown to be associated with neuropsychi-
atric diseases such as 16p11.2 to autism and 22q11.21 to
schizophrenia. However, controversy remains as to whether
rare events impacting certain pathways as a group increase
the risk of disease, and if so, what those pathways are. Other
studies have used standard gene-set enrichment approach-
es to demonstrate that events discovered in cases contain
more genes in neuro-developmental pathways than would
be expected by chance. However, these analyses do not
explicitly compare the relative enrichment in cases to any
enrichment that may also be present in controls. Therefore,
they can be confounded by the large size of brain genes or
by larger size or frequency of CNVs in cases. Here we
propose a case-control statistical test to assess whether a
key pathway is differentially impacted by CNVs in cases
compared to controls. Our approach is robust to skewed
gene sizes and case-control differences in CNV rate and size.
Pathway Analyses of Genes Affected by Rare CNVs
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Results and Discussion
Standard enrichment analysis to test gene sets affected
by rare CNVs
Set enrichment is the standard approach to test whether genes
impacted by CNVs in cases affect specific pathways. Specifically,
the overlap between the set of genes affected by CNVs is
compared to the set of genes with a particular function.
Genes affected by a CNV might be defined as disrupted genes or
overlapped genes. Disrupted genes are those genes that have a CNV
boundary that falls within the boundaries of its transcript [1].
Overlapped genes are a superset of those genes whose transcripts are
either disrupted by a CNV or are fully contained by a CNV [8].
Since genes rarely overlap each other, a single CNV event might
contribute up to two disrupted genes but many overlapped genes. Both
have been previously examined in the literature. Unless otherwise
specified, this study emphasizes overlapped genes.
After identifying the genes affected (overlapped or disrupted) by a
CNV, we then identify genes with a specific process or within a specific
pathway. We apply a two-tailed Fisher’s test to assess whether the
number of affected pathway genes is statistically significantly different
than might be affected by chance. The critical assumption in gene set-
based analyses is that there is a single independent observation per
gene, not connected to the gene’s size or structural features.
A case-control framework to test gene sets affected by
rare CNVs
As an alternative, we propose a simple case-control strategy to
test gene sets or pathways for association to disease: the ‘‘cnv-
enrichment-test’’. This strategy is consistent with the case-control
association framework used in CNV and SNP disease association
studies [21,22]. A direct case-control comparison avoids any
ascertainment bias that might be the consequence of structural
features of genes within a set, since the same biases will apply
equally to both cases and controls.
We are careful to control for case-control differences in CNV
rate and size, since those differences can artificially induce a
pathway association. For example, if the rare CNV rate in cases is
more frequent or larger than in controls, then on average all genes
will be impacted more often in cases, and any arbitrary gene set
might appear to be affected more commonly in cases than in
controls. Also, if rare CNVs are smaller but more frequent in cases
than in controls, then sets of larger genes might appear to be
impacted more often in cases than in controls.
To assess whether CNV events specifically overlapping genes in
the pathway of interest are enriched in cases compared to controls,
we propose the following logistic model:
log
pi,case
1{pi,case
 
~hzb0
:cizb1
:sizc:gize
where pi is the probability that individual i is affected, ci is an
integer that indicates the number of rare CNVs that an individual i
has, si is the average size of those events, gi is the count of gene
within a pre-specified gene set affected by a cnv, and e is an error
term. The terms h, c, b0, and b1 are logistic regression parameters
that are optimally determined to maximize the likelihood of the
data. The h term (the intercept) represents the background log
likelihood for each individual, c is the increase in log-likelihood per
affected gene within the gene set, b0 is the increase in log-
likelihood per rare CNV, and b1 is the increase in log likelihood
per kilobasepair of average rare CNV size. The cnv-enrichment-test
simply tests if c is significantly different from 0.
In principle, previous studies in schizophrenia that have shown
excess CNVs in affected individuals corresponding to a positive b0.
It has also been demonstrated that individuals with neuropsychi-
atric disease often have larger events, consistent with a positive b1
term. On the other hand, if there is a ‘‘causal’’ gene set g, then
adding it to the model should attenuate the magnitude of both b0
and b1 and result in a convincingly positive c. An independent
odds ratio estimate, ec, can be calculated for the additional
increased risk of disease if an event affects a gene in set g.
This approach is not confounded by functionally related genes
that cluster on the genome. Since risk is estimated on a per
individual basis, a single spurious observation will not dramatically
impact the statistical significance of any of the parameter
estimates. So, a rare single event, which happens to overlap
multiple related genes within the gene set that is being tested, will
not contribute substantially to the significance of c - even though
potentially many genes from that pathway are implicated. Of
course, if many such events are observed, with a proclivity towards
either cases or controls, then estimates for cmight appropriately be
more significant.
The approach can be extended to do a meta-analysis if patient
data is aggregated, and indicator variables are included to denote
the dataset that the patient sample was derived from. Indicator
variables would potentially account for specific differences across
data sets, such as the proportion of individuals that are cases and
also underlying biases in case severity.
This approach can be facilely applied to gene-sets ranging
widely in size. It can equally be applied to a single gene, for
example to identify whether a gene such as NRXN1 has more case-
events than control-events after controlling for genome-wide
differences in CNV size and rate. It can also be easily applied to
the set of all genes in the human genome to test if genes in general
are more often affected in cases than controls. We caution that in
data sets with too few individuals, association to smaller gene sets
might be difficult to detect given power limitations; furthermore
the asymptotic p-value might be inaccurate. In cases where too few
events have been genotyped the asymptotic p-value can be
replaced by a p-value based on robust permutation testing instead.
We have implemented this test in the publicly available genetic
data analysis software, PLINK [23].
CNV-enrichment-test is robust to skewed gene size, even
if there are case-control differences between the size and
rate of CNVs
To demonstrate that the cnv-enrichment-test does not detect
spurious associations due to gene features that predispose key gene
sets towards CNVs, we carefully considered gene size. We created
an extreme hypothetical scenario (S0, see Table S2). Here, every
fifth gene was designated as a hypothetical ‘‘brain gene’’; brain
genes were set to be considerably larger than other genes (50 kb
versus 10 kb). For a single hypothetical chromosome, 250 Mb in
length, we placed 2000 evenly spaced, non-overlapping genes. In
all scenarios we simulated CNV data for 2000 cases and 2000
controls, specifying the mean CNV size at 100 kb (range 10 kb to
150 kb, standard deviation 30 kb) and the CNV rate per
individual at 0.25. Reassuringly, in this simulation cnv-enrichment-
test for ‘‘brain-genes’’ demonstrated p,0.05 association in 4.1% of
10,000 simulated datasets, suggesting that it estimates the type I
error rate accurately (see Figure 1).
However, in practice, differences between the size and rate of
CNVs might be present due to true genetic differences between
cases and controls, as demonstrated in neuropsychiatric disease, or
technical differences in array intensity or genotyping platform.
Pathway Analyses of Genes Affected by Rare CNVs
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Our method must be robust to these differences and must not
spuriously identify pathways with large genes as a consequence of
these differences. To test for this we created four extreme scenarios
(S1–S4, see Table S2). Under S1, we dramatically reduced the
control rate of CNVs to 0.05/individual while retaining the same
rate in cases (0.25/individual). Under S2, we fixed the rate at
0.25/individual in both cases and controls, but reduced the mean
CNV size in cases (60 kb) compared to controls (100 kb). Under
S3, we assigned cases the greater rate and mean size (0.25/
individual and 100 kb) compared to controls (0.05/individual and
60 kb); this scenario is analogous to schizophrenia where events
are larger and more frequent in cases. Under S4, we assigned cases
had a greater rate, but smaller mean size (0.25/individual and
60 kb) compared to controls (0.05/individual and 100 kb); this
scenario might occur if higher quality genotyping is applied in
cases only resulting in better ability to detect smaller CNVs than in
controls. We found that the proposed method that controlled for
both CNV rate and average CNV size was robust under each of
these extreme scenarios and for 10,000 simulated datasets
demonstrated appropriate type I error rate at p,0.05 under all
scenarios (see Figure 1).
To illustrate the importance of controlling for CNV rate and
size in this setting where a pathway consists of systematically larger
genes, we examined more limited models that do not control for
either or both the CNV rate and size. All of these models caused
inappropriately high type I error rates under at least one of the
above scenarios (see Figure 1) and would demonstrate spurious
association to ‘‘brain genes’’. A simple association test (M0) that
does not account for either for CNV rate or size at all
demonstrates higher rates of false associations under all simulated
scenarios where there are case-control differences in size and rate
of CNVs (S1–S4). Similarly, controlling for differences in rate only
(M1) demonstrates higher rates of false associations under almost
all simulated scenarios, except for S0 and S1. Controlling for
differences in size only (M2) demonstrates higher rates of false
associations under almost all simulated scenarios, except for S0
and S3. Finally, controlling for differences in total CNV burden
(M3) demonstrates higher rates of false associations under S3 and
S4 all simulated scenarios.
Four plausible sets of genes with brain function
To broadly define genes that control brain function, we used a
gene expression tissue atlas to define a broad set of 2,531
preferentially brain-expressed genes (seeMaterials and Methods).
For secondary analyses, we compiled three more sets of general
interest to neuropsychiatric disease: (1) 455 neuronal-activity genes
defined by Panther and highlighted previously in schizophrenia by
Walsh et al [1], (2) 126 learning genes defined by Ingenutiy and
highlighted by Zhang et al in bipolar disease [8], and (3) 209 synapse
genes defined by Gene Ontology. The gene sets overlap; 12 genes
are in all four sets.
Application of set enrichment to rare CNVs in controls
demonstrates that brain function genes are enriched
To demonstrate some of the limitations associated with standard
set enrichment tests to assess critical gene functions examined the
aforementioned gene sets in rare CNVs from controls recruited
from the general populations. We used Affymetrix 6.0 chips in
conjunction with stringent and uniform quality control to
genotype 2,415 unaffected individuals (see Table S3 and Table
S4) from four separate studies [8,24–26]; hereafter referred to as
‘meta-controls’. We identified 1,054 single event deletions ranging
from 20 kb to 1.9 Mb in size. To obtain the most confident calls
possible, we focused only on deletions (see Materials and
Methods) – though including duplications does not substantially
impact our results.
Strikingly, many of the genes that are disrupted (and therefore
also overlapped) by rare deletions within the meta-controls have
been proposed as candidate genes for neuro-developmental
diseases including: GRM5, GRM8, FHIT, OPCML, PTPRD,
NRXN3, NRG3, CNTNAP2, AUTS2, CTNNA3, DLG2, ERBB4,
PTPRM, and NRXN1. All of these genes are among the largest in
the human genome, with transcripts extending from 550 kb to
Figure 1. Performance of each of the five proposed models (M0–M4) across five hypothetical scenarios. For each of the scenarios (S0–
S4) outlined in Table S2 we simulated 10,000 datasets to calculate the type I error rate for the enrichment test, for a nominal rate of 0.05. Only the
model M4, controlling for CNV rate and average size, obtains an appropriate type I error rate under all scenarios where case-control differences in
size and rate are presence. Other models, fail to adequately control for these confounders. The M4 model is presented in the main text as the cnv-
enrichment-test.
doi:10.1371/journal.pgen.1001097.g001
Pathway Analyses of Genes Affected by Rare CNVs
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2.2 Mb of genome. Except for GRM5 and PTPRM, they are all
greater than 1 Mb in length. In particular DLG2, ERBB4, PTPRM,
and NRXN1 were disrupted by 12 individual events in our study;
Walsh et al. highlighted these four genes as potentially pathogenic
based on pathway analysis [1].
As previously observed by Redon et al [14] and Yim et al [15],
genes affected by rare CNVs are involved disproportionately in
brain function in this control population. The set of genes
disrupted by deletions within the meta-controls are enriched for
brain-expressed genes (OR=2.0, p=261028) and other brain
function gene sets as well (see Figure 2). The enrichment is present,
though somewhat less pronounced, if all genes overlapping
deletions are included (OR=1.63, p=461026, see Figure 2).
Gene size confounds gene set enrichment approaches
To explain this enrichment of rare CNVs affecting brain-function
genes in controls, we conjectured that the gene set enrichment
approach is confounded by gene size. Three observations support
this possibility. First, the transcripts of brain-expressed genes are
significantly larger than of other human genes (p=9610282 by non-
parametric rank-sum test, see Figure 3A). The median length of all
human gene transcripts is 28.2 kb; in contrast the median length of
brain expressed gene transcripts is 47.2 kb (1.7 fold longer). In fact
of the genes longer than 1 Mb, 32 out of 48 (67%) are brain-
expressed. Genes in the three other gene sets are also significantly
longer (1.2–3.1 fold). Second, we note that the genes affected by
CNVs are also large. Genes disrupted by events in these meta-
controls, as well as previously published data sets by Zhang et al,
Walsh et al, and the ISC were large (p,2610210, see Figure 3B).
The bias towards large genes is still present, though mitigated, if the
analysis is expanded to include all overlapping genes (p,0.01, see
Figure 3B). Smaller genes overlapping a CNV are much more likely to
be fully contained by that CNV while larger genes are more likely to
extend beyond the boundaries of the CNV and hence be disrupted by
that CNV. Third, almost all gene ontology [13] (GO) categories
consisting of genes with an average size .200 kb are preferentially
affected by rare deletions within the meta-controls (see Table S5).
These codes implicate functions such as cell adhesion and
recognition, neuron recognition, and synaptic pathways.
Random genomic segments also demonstrate
enrichment for brain genes
To quantify the extent to which observed enrichment for these
gene sets was simply a consequence of their large size, we tested
whether randomly placed genomic segments affect genes with
brain function genes preferentially also (see Table 1). We created
1,000 sets of 1,054 randomly positioned non-overlapping segments
of equal size and probe density as those rare deletions observed in
Figure 2. Neurodevelopmental gene sets are enriched in CNVs for affected and unaffected individuals. Here we present results from
three gene sets – neuronal-activity genes (A), brain-expressed genes (B), learning genes (C), and synapse genes (D). For each set we calculate
enrichment among genes disrupted by rare CNVs with a Fisher’s exact test in meta-controls and also within the affected and unaffected individuals in
the Walsh et al. study and the ISC study. We explicitly list all p-values ,0.1. Each point represents an odds ratio and is plotted with a 95% confidence
interval. A comparable degree of enrichment was observed across all data sets for each of the gene sets.
doi:10.1371/journal.pgen.1001097.g002
Pathway Analyses of Genes Affected by Rare CNVs
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the meta-controls (see Materials and Methods). Brain-
expressed genes were enriched among overlapping genes
[OR=1.67 (1.17–2.26)] and disrupted genes [OR=2.08 (1.71–
2.49)]; the enrichment for brain expressed and other brain genes
sets was comparable to the enrichment in observed data.
However, there are two key differences in the results of real rare
CNVs and simulated CNVs. Observed rare deletions overlap 35%
fewer genes than random segments – suggesting unsurprisingly
that deletions overlapping genes are selected against. Possibly,
events affecting potentially critical genes that, if affected, disrupt
normal human development are selected against. But, on the other
hand, the pattern for the largest genes is strikingly different – the
observed rare deletions actually overlap 26% more of those genes
.1 Mb in length than random segments. This suggests a
predilection for large genes that cannot be accounted for simply
by their larger genomic footprint.
Gene size, structure, and genic density all independently
predict whether a gene is independently affected by a
CNV
To explain the discrepancy between the size and number of
genes affected in real CNVs and simulated segments, we
speculated that while rare events affecting genes are negatively
selected against, those that affect large genes might be less strongly
selected against. Possibly, large genes have certain structural
features that tend to make them relatively preferred targets of rare
CNVs above and beyond their simple large size. For example, a
CNV within a long gene might be more likely to fall within a large
intron and not disrupt the coding sequence, and therefore have
less-clear relevance to gene function. Furthermore, since genes
tend not to overlap, a CNV of a particular size that overlaps larger
genes may affect fewer genes than one that overlaps many smaller
genes, and may therefore be less likely to impact some nearby
essential gene.
To test whether these factors might play a role we tabulated
three relevant structural features for each gene (see Materials
and Methods): (1) transcript length, (2) a gene neighborhood
density score, representing the expected number of additional
nearby genes that a randomly placed CNV affects, and (3) a gene
structure score, that represents the expectation that a randomly
placed overlapping deletion is fully intronic. The first parameter
simply accounts for the size of the ‘target’. The other two
parameters account for the possibility that CNVs overlapping
certain genes might be more likely to be functionally consequen-
tial. We found that all of these variables individually correlated
with the likelihood that a gene is overlapped by deletions in meta-
controls (see Figure S1). We then conducted a conditional analysis
and found that even though they are inter-correlated, they each
independently predict the probability that a gene is deleted in the
meta-controls – removal of any single parameter significantly
affects a logistic regression model’s predictive ability (see Table 2).
The additional factors of gene density and structure could account
for the reduced number of affected genes overall and the increased
proportion of larger genes compared to random segments in the
genome.
Figure 3. Genes with brain function and genes impacted by CNVs are large. A. Brain-expressed, neuronal-activity, learning, and synapse
gene sets consist of large genes. For each gene set we plot the length of each gene, relative to the median length of human genes (28.2 kb).
Median gene length is labeled and represented by a horizontal line. Box indicates the range of gene lengths (2.5%–97.5%). Outliers are plotted as
dark points outside the box. For each gene set we compared the length of genes within the set and outside the set with a two-tailed rank-sum
p-value. B. Genes overlapping and disrupted by rare CNVs are large. For each data set we plot the length of genes overlapping (left) and disrupted
by (right) rare CNVs, relative to the median length of human genes (28.2 kb). Median gene length is labeled and represented by a horizontal line.
Box indicates the range of gene lengths (2.5%–97.5%). Outliers are plotted as dark points outside the box. For each set we compared the length of
genes affected and not affected by CNVs with a two-tailed rank-sum p-value. To allow for consistent comparisons, we restricted meta-control
events to those .100 kb.
doi:10.1371/journal.pgen.1001097.g003
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One possible strategy to correct gene set based analyses is to
devise a score that encapsulates the structural features of genes,
and their predicted propensity to be affected by a CNV. This
provides a robust approach to assess pathway enrichment in he
suboptimal situation when controls are not available (e.g. when
evaluating a collection of de novo case-only Autism deletions). We
present such a CNV-propensity gene score (CNVprop) that
represents an empirical estimate of the log-likelihood that a gene
is overlapped by a CNV based on gene structural features based
on the parameters from Table 2. CNVprop can be used as a
covariate within a logistic regression framework in assessing
enrichment of a gene set. We provide the CNVprop scores of genes
in Table S6. While other methods to correct for gene size have
been proposed in the literature, they do not specifically account for
additional effects from gene density and intron structure, which
are likely specific to CNV events. This approach, however, is still
not ideal since it fails to account for multiple genes contributed by
a single event, or genes being affected multiple times by an
individual CNV event.
Gene enrichment of brain function genes in
schizophrenia case and control CNVs are equivalently
significant
To further demonstrate application of gene set analysis and its
potential pitfalls, we used a large data set published by the ISC
with many rare (,1% frequency) deletions and duplications
identified from 3,391 affected by schizophrenia and 3,181
unaffected individuals (see Table S3).
In order to replicate the analysis published by Walsh et al [1],
we conducted set-based analyses of genes disrupted by CNV
events within the ISC cases. We observed enrichment of brain-
expressed genes (p=3610211, two-tailed Fisher’s exact, Figure 2).
However, when we examined genes disrupted within controls in the
ISC, we observed similar evidence for brain-expressed genes
(p=3610210, see Figure 2). Critically, the odds ratios (ORs) for
enrichment of brain-expressed genes among genes disrupted in
affected individuals and unaffected individuals were difficult to
distinguish in this analysis. We observed similar trends towards
enrichment for brain-expressed genes overlapped by CNVs
(OR=1.1, p=0.06 for cases, OR=1.08, p=0.20 for controls,
data not shown) and overlapped by very rare single event CNVs
(OR=1.5, p=0.004 for cases, OR=1.6, p=0.01 for controls,
data not-shown). Furthermore, with the exception of the learning
genes, all brain function gene sets demonstrated significant
enrichment within ISC cases and controls (see Figure 2).
We applied the same analysis to a data set with a small number
of CNVs published by Walsh et al and demonstrated similar effects
(see Figure 2). Cases tended to be more statistically significant for
all of the gene sets than controls, since they were better powered
with more affected genes. However, confidence intervals were
wide in this analysis, and it was unclear it there were true case-
control differences.
In both data sets – while statistically significant enrichment for
brain function genes is observed in cases, it is not clear that the
effect size is any different than in controls.
Table 1. Properties of observed deletions in the meta-
controls versus randomly placed simulated deletions.
Meta-Controls
(observed rare
deletions)
Simulated
Segments
Segments
N 1054 1054
Median Length (kb) 51.1 51.1
Overlapping $1 Gene 412* 530 (498–557)
Disrupting $1 Gene 359* 472 (442–499)
Overlapping Genes
N 538* 818 (739–900)
Gene length (median, kb) 65.7 57.1 (45.5–71.2)
.100 kb length genes 225* 311 (284–339)
.500 kb length genes 74 74 (62–87)
.1Mb length genes 29* 23 (17–29)
Brain-Expressed (OR) 1.63 1.51 (1.26–1.77)
Neuronal Activity (OR) 1.61 1.67 (1.17–2.26)
Synapse (OR) 2.04 1.98 (1.28–2.93)
Learning (OR) 1.78 1.71 (0.86–2.78)
Disrupted Genes
N 345* 497 (462–532)
Gene length (median, kb) 162.9* 131.8 (115.9–152.1)
Brain-Expressed (OR) 2.04 2.08 (1.71–2.49)
Neuronal Activity (OR) 1.84 2.25 (1.50–3.07)
Synapse (OR) 2.33 2.85 (1.82–4.24)
Learning (OR) 2.84 2.25 (0.98–3.81)
Here we compare the observed properties for rare deletions in meta-controls to
that of 1000 simulated random segments, matched for size and probe-density.
For simulated random deletions for each property, we list the median value, and
in parentheses we list the 95% range. We have noted values from observed
deletions that deviate (p,0.05) from the simulations with asterisks (*). The first
set of values compare observed rare deletions to random segments. The
number and median length are the same since segments were matched for
these properties. In the next two lines we list the numbers of overlapping and
disrupted genes. The next set of values compare data on the set of genes
overlapping observed deletions to simulated segments. We list the number of
overlapping genes altogether, and exceeding specific gene length thresholds
(100 kb, 500 kb, and 1 Mb). Finally we list the odds ratio for the three brain-
function gene sets for the set of overlapping genes. The final set of values
compare similar data on the set genes disrupted by rare deletions to simulated
segments. Disrupted genes stratified by length is not shown, and is similar to
that of overlapping genes.
doi:10.1371/journal.pgen.1001097.t001
Table 2. CNV-propensity score parameters.
Multivariate Analysis
Parameter b p (model)
Gene size (Mb) 2.40 (1.78–3.01) 1.2610217
Gene neighborhood density
(genes/CNV)
20.11 (20.15–20.07) 1.461027
Gene structure score 1.31 (0.27–2.33) 0.019
Intercept 23.31 (23.46–23.15)
Each of the three parameters significantly improves the likelihood model
predicting whether a gene overlaps a rare deletion within the meta-controls.
We tested three parameters: (1) the gene size, which represents a
straightforward parameter representing the length of the gene in Mb, (2) the
gene neighborhood density score is the average number of additional
genes that a CNV overlapping the gene overlaps, and (3) the gene structure
score which is the proportion of CNVs overlapping a gene that is fully intronic.
For each parameter we list the multivariate logistic regression beta and 95%
confidence interval. We also list the statistical significance of the change in log-
liklihood by removing the variable from the model.
doi:10.1371/journal.pgen.1001097.t002
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Application of cnv-enrichment-test to previously
published schizophrenia data sets
We applied the case-control cnv-enrichment-test to check CNVs
published by the ISC and by Walsh et al to test whether case
events were enriched for genes with brain function relative to
controls. In the ISC data, we had already reported elsewhere
increased genome-wide rates and sizes for case CNVs [2]. Walsh
et al had demonstrated genome-wide enrichment separately.
We applied the cnv-enrichment-test to the four gene sets (brain-
expressed, neuronal-activity, learning and synapse as described above).
The results in Table 3 report the empirical 1-tailed p-values for a
test of enrichment of the genes in the set relative to the genome-
wide baseline rates of all CNVs; for the smaller gene sets standard
asymptotic tests yielded unreliable estimates, due to the sparse
nature of the data (for example 7 case events, 0 control events for
neuronal genes in Walsh et al). In this context, the empirical
significance values obtained via permutation will be robust to these
sparse cell counts. Of course, for the larger gene sets, and all of the
gene sets in the larger ISC data set, analytical p-values
corresponded closely to permuted p-values.
There was no evidence of enrichment among case-CNVs
compared to control CNVs for brain-expressed and synapse genes
(p.0.12, one-tailed analysis, see Table 3). This is in marked
contrast to the observed enrichment of these same brain gene sets
in the case-only analyses presented in Figure 2 that did not
account for gene size.
However, the neuronal-function gene set demonstrated evidence of
association to schizophrenia cases for both Walsh et al
(p=0.00045) and the ISC data (p=0.04). There was also evidence
of association of the learning gene set within the ISC data (p=0.009)
but not in the Walsh et al data (p=0.35).
We want to emphasize that these results are not adjusted for
multiple hypotheses testing – and the plausible number of
independent gene sets. In this study alone we have tested four
separate gene sets. Ultimately, convincing associations will require
larger data sets. As additional samples are genotyped for CNVs,
the relevance of the neuronal-function genes might be more clearly
established.
Of note, considering only deletions within the ISC data, the
effect of neuronal-function gene set enrichment is stronger
(p = 0.0067, with higher rates in cases). Similarly, considering
only deletions within the ISC data, the effect of the learning gene set
enrichment is also stronger (p = 0.002, with higher rates in cases).
In both cases neuronal-function and learning gene sets, the effect
sizes associated with an event affecting a gene is modest ranging
from 1.2–1.7. This suggests that even if the set associations are
ultimately validated, that rare CNV events affecting genes within
these sets certainly do not fully explain the pathogenicity of rare
CNVs.
Conclusions
The cnv-enrichment-test is an extremely versatile test to identify
whether a gene set of interest is associated with case-control status.
We have shown that it is robust to confounders, such as case-
control differences in CNV rate and gene size, while standard gene
set enrichment approaches are not.
Since the cnv-enrichment-test can be applied easily to a wide range
of gene sets, there may be the temptation to examine data sets by
testing a compendium of gene-sets. Generally, we discourage this
approach, and urge investigators to look at specific sets of interest.
Assessing the significance of association statistics when testing a
large compendium of gene-sets is complex since there is a large
number of highly overlapping sets; correcting for the large burden
of multiple hypotheses testing appropriately can be challenging.
However, should one decide to test such a compendium of gene-
sets, it is important that investigators permute the case-control
status within their own data set, and apply the same battery of tests
to make sure that the actual data set is obtaining levels of
significance that are beyond that of the permuted data sets.
We have also shown that pathway analyses with standard gene set
enrichment approaches are confounded by gene size and structure.
This issue is of particular importance when considering genes with
brain function – since those genes are significantly larger than other
human genes. We have demonstrated how a large set of brain-expressed
genes seem to be impacted by CNVs in both case and control
populations when using gene set enrichment approaches, and how
this effect is largely the consequence of the size of these genes. The
brain-expressed genes were selected for having significantly greater
expression in neuronal tissues as opposed to non-neuronal tissues.
Certainly genes with important brain functions that are ubiquitously
expressed in all tissues might be missed by such a strategy, as might
genes with very low expression levels overall. However, we observed
very similar results for three other separately curated sets of genes
with brain function; this suggests that gene size and spurious pathway
associations may be of particular importance for brain function genes.
The approach we describe here can be applied more broadly
than within the context of CNVs; the cnv-enrichment-test can be
applied to any situation where disease-associated genomic segments
are defined. For example, linkage disequilibrium blocks around
associated SNPs can be defined as disease-associated genomic-
segments. The potential for gene size and structure confounding
pathway analyses extends beyond CNV studies, and applies equally
to pathway analyses within other types of genetic studies, including
SNP association studies, as noted by Wang et al [27] and exon re-
sequencing studies. For example, in a study looking at classes of
Table 3. Assessing if brain-function genes increase schizophrenia risk in published CNV data sets.
Gene Set ISC Walsh et al
OR= (ec) P (empirical, 1 tailed) OR= (ec) P (empirical, 1 tailed)
Brain-Expressed 1.03 0.19 1.11 0.41
Neuronal Activity 1.18 0.038 N/A 0.0004
Learning 1.38 0.0085 1.66 0.35
Synapse 0.97 0.58 3.35 0.12
We used the cnv-enrichment-test to test whether any of four brain function gene sets were enriched in two CNV published datasets. In the first column we list the tested
gene set. In the second two columns we list results for the ISC data set, and in the final two columns we list results for the Walsh et al data set. For each data set we
present the odds ratio for schizophrenia for each gene set and the one-tailed empirical p-value.
doi:10.1371/journal.pgen.1001097.t003
Pathway Analyses of Genes Affected by Rare CNVs
PLoS Genetics | www.plosgenetics.org 8 September 2010 | Volume 6 | Issue 9 | e1001097
genes that are disproportionately affected by rare exonic mutations,
the total length of the coding sequence will be a key confounding
variable. Similarly, studies looking at classes of genes that contain a
single SNP nominally associated to disease, confounding variables
might include the number of independent SNPs examined, the
physical size of the gene, and the recombination hotspots across the
length of the gene. In any case, careful case-control comparisons are
essential to avoid these confounders.
Many of the genes involved in brain function are compelling
candidate genes for neurological and psychiatric diseases – and
indeed they may be the most vulnerable to CNVs. The purpose of
this manuscript is not to question the results of the original
publications, but to rather set up a rigorous statistical approach
that allows investigators to accurately estimate effect sizes of events
impacting specific gene sets of interest and also to precisely
replicate reported results.
Materials and Methods
Compiling Gene Sets
Brain-Expressed. To identify genes with specific expression in
the brain, we obtained a large publicly available human tissue
expression microarray panel (GEO accession: GSE7307) [28]. We
analyzed the data using the robust multi-array (RMA) method for
background correction, normalization and polishing [29]. We filtered
the data excluding probesets with either 100% ‘absent’ calls (MAS5.0
algorithm) across tissues, expression values ,20 in all samples, or an
expression range,100 across all tissues. To represent each gene, we
selected the corresponding probeset with the greatest intensity across
all samples. We included expression profiles from some 96 healthy
tissues and excluded disease tissues and treated cell lines. We
averaged expression values from replicated tissues averaged into a
single value. To assess whether genes had differential expression for
CNS tissues, we compared the 27 tissue profiles that represented
brain or spinal cord to the remaining 69 tissue profiles with a one-
tailed Mann-Whitney rank-sum test. We identified those genes
obtaining p,0.01 as preferentially expressed.
Synapse. We downloaded Gene Ontology [30] structure and
annotations on December 2006. Since it was available, we used a
previous version of Gene Ontology to ensure independence from
the results of recent genetic scans. We expanded human gene
annotations to include annotations from orthologous genes,
identified through Homologene [30] from model organisms. We
identified those genes that were annotated with the ‘Synaptic
Junction’ code (GO:0045202), or descendents of that code.
Neuronal Activity. We downloaded the list of genes within
the category ‘Neuronal Activities’ (BP00166) listed in the Panther
database [12].
Learning. We downloaded the list of genes within the
category ‘Behavior-Learning’ listed in the Ingenuity Application.
To avoid spurious results and focus on a consistent set of genes
across all studies, we included in our analysis only autosomal genes
that (1) had at least one annotations in GO and (2) passed quality
control criteria in the data set used to identify brain-expressed
genes. The resulting set consisted of 14,565 annotated genes.
Obtaining Walsh CNV data
We obtained rare event deletions and duplications from Table 2
in the original publication of the data [1].
Obtaining ISC CNV data
Rare (,1% frequency) event deletions and duplications were
provided directly by request from the International Schizophrenia
Consortium.
Identifying Rare CNVs in the Meta-controls
We obtained data from unaffected individuals with informed
consent from four Institutional Review Board approved studies:
macular degeneration [26], myocardial infarction [25], bipolar
disease [8], and multiple sclerosis [24]. We obtained Affymetrix
6.0 raw intensity data for all samples and ran the Birdsuite
software on each plate individually [31]; CNV calls were based on
Birdseye output. We then analyzed healthy unaffected individuals
from each of four studies separately. First we filtered individuals on
SNP data, removing individuals with .5% missing data. Second,
in situations where Birdseye called two nearby segments (,10 kb)
with identical copy number and there was a low confident segment
in between (LOD,3), we merged those segments. Third, we
exclude all CNVs that (1) overlap CNVs from a map of common
variation [32], or (2) failed stringent quality control criteria
(,20 kb in length or ,10 LOD or ,10 probes). Fourth we
removed those individuals in each study that were outliers in either
excessive number of CNVs, or in excessive aggregate length of
CNVs – we defined outlier as the median plus the 1.5 times the
inter-quartile range. We then combined all CNVs into a single
data set, and identified single-events (i.e. non-overlapping)
deletions.
Placing Genomic Segments
We produced 1000 sets of non-overlapping segments through-
out the genome. Each set consisted of segments matched for size
and probe-denisty (+/210%) to each observed single-event
deletions in meta-controls. Since we were simulating rare events,
random events were not allowed to overlap regions with known
copy number variation [32] or in regions where we observed an
overlapping event (i.e. not a singleton) in the meta-controls.
Defining Gene Parameters
For each gene we defined three parameters (1) gene length, (2)
gene neighborhood density score, and (3) gene structure score.
Gene length was simply the length of the gene transcript in
mega-basepairs.
To calculate a neighborhood density score for a gene, we
consider a CNV overlapping a gene. The neighborhood density
score is then the expected number of additional nearby genes
overlapped by the same CNV. To empirically estimate the
distribution of sizes of rare CNVs, we utilized the sizes, s, of
observed single event deletions in the meta-controls. Then to
calculate the gene neighborhood density score, gdi, for gene i, we
used the following formula:
gdi~
P
s[observed
size
P
p[genomic
positions
overlapi(p,s):ðoverlapall(p,s){1Þ
P
s[observed
size
P
p[genomic
positions
overlapi(p, s)
where p is a genomic position, overlapi(p, s) is an indicator function
that is 1 if a segment of length s starting at position p overlaps gene
i, or is otherwise 0. Similarly overlapall(p, s) is the number of genes
that a segment of length s starting at position p overlaps. In the
numerator we subtract one off, since we want to exclude gene i
itself
To calculate a gene structure score, we calculated the expected
proportion of overlapping CNVs that would not affect the coding
sequence of the gene (i.e. be fully intronic). To empirically estimate
the distribution of sizes of rare CNVs, we again used the sizes, s, of
observed single event deletions in the meta-controls. Then to
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calculate the gene structure score, gsi, for gene i, we used the
following formula:
gsi~
P
s[observed
size
P
p[genomic
positions
overlapi(p,s):intronici(p, s)
P
s[observed
size
P
p[genomic
positions
overlapi(p, s)
where p is a genomic position, overlapi(p, s) is an indicator function
that is 1 if a segment of length s starting at position p overlaps gene
i, or is otherwise 0. Similarly intronici(p, s) is an indicator variable
that is 1 if a segment of length s starting at position p does not
overlap a coding sequence, or otherwise is 0.
Statistical Models to Assess Gene Set Enrichment Across
CNVs
In order to produce a framework to test gene-sets and their
association to disease, we used a linear/logistic regression
framework in which phenotype is regressed on the number of
genes intersected (or disrupted) by one or more CNVs and
covariates. We considered five different models to test for
enrichment of CNVs in a pathway of interest, and tested them
with simulated datasets.
For a disease outcome, a standard model, M0, is as follows:
log
pi,case
1{pi,case
 
~hzc:gize
where for individual i, gi is the number of genes in a pathway of
interest that intersected/disrupted by a CNV. The h term is the
logistic regression intercept and represents the background log
likelihood for each individual, while c is the logistic regression
parameter for gi.
Model M1 controls for potential genome-wide differences in
CNV burden between cases and controls:
log
pi,case
1{pi,case
 
~hzb0
:cizc:gize
where ci is the total number of CNVs in a given individual i. The
b0 term is the logistic regression parameter for ci.
Model M2 alternatively controls for CNV size:
log
pi,case
1{pi,case
 
~hzb1
:sizc:gize
where si is the individual’s mean CNV size in kb. If for a particular
individual ci=0 (i.e. they do not have any CNVs) then si is set to
the sample mean of s rather than 0 or missing. (Otherwise, if many
individuals have no CNVs, a strong correlation will be induced
between the rate and average size of CNVs.) The b1 term is the
logistic regression parameter for si.
Model M3 alternatively controls for an individual’s total CNV
burden expressed in terms of total kb deleted or duplicated,
written here as the product of ci and si:
log
pi,case
1{pi,case
 
~hzb2
: ci:sið Þzc:gize
The b2 term is the logistic regression parameter for (ci?si).
Finally, the cnv-enrichment-test model controls explicitly for
potential case/control differences in both the number and size
distributions of CNVs:
log
pi,case
1{pi,case
 
~hzb0
:cizb1
:sizc:gize
This is the model introduced in the main text labeled as the ‘‘cnv-
enrichment-test’’. As above, if for a particular individual ci=0 (they
do not have any CNVs) then si is set to the mean size of all CNVs
in the sample as opposed to zero.
Under all circumstances, the null hypothesis for the 2-sided test
of enrichment is H0: c=0.
Testing Models in a Simulated Case-Control Framework
We conducted simulations to understand the performance
characteristics of these different analytic approaches (M0–M3 and
cnv-enrichment-test) to test for enrichment of case CNVs in a set of
genes. We explicitly adopt extreme conditions in these simulations,
to best illustrate the robustness of each approach under the
broadest range of conditions.
For each individual, we simulated data for a single hypothetical
chromosome, 250 Mb in length. We placed 2000 evenly-spaced,
non-overlapping genes on the hypothetical chromosome, where
every fifth gene was designated as a ‘‘brain gene’’. We assigned
brain genes to be considerably larger than other genes (50 kb
versus 10 kb). In all scenarios we simulated CNV data for 2000
cases and 2000 controls. For cases and controls, the mean CNV
size was either 60 kb or 100 kb, as detailed in Table S2 (range
10 kb to 150 kb, standard deviation 30 kb). Under all scenarios,
individuals had either 0 or 1 CNV, with rates given in Table S2.
All datasets were simulated under the null hypothesis of no
enrichment for brain genes; that is, CNVs were randomly placed
on the hypothetical chromosome, similarly for both causal and
controls. Under five scenarios, S0 to S4, we altered the mean
CNV rate and CNV size for cases and controls independently, in
order to induce enrichment of CNVs in brain genes arising solely
as a consequence of CNV rate and size. Under the first scenario,
S0, there were no differences between cases and controls in the
rate and size of CNVs: we therefore expected all methods to give
appropriate type I error rates here. Under S1, the rate of CNVs
was higher in cases. Under S2, the average CNV size was smaller
in cases. Under S3, cases had a greater number, and larger, CNVs
than controls. Under S4, cases had a greater number, but smaller,
CNVs than controls.
For each scenario, we simulated 10,000 datasets to calculate the
type I error rate for the enrichment test, for a nominal rate of 0.05.
Implementation
This test is implemented in PLINK v1.07 (–cnv-enrichment-
test). It is appropriate for either continuous or disease traits and
allows for the inclusion of multiple other covariates and for
empirical significance tests.
The following examples illustrate basic usage. If the file
genes.dat contains the locations of all genes (i.e. as available from
the resources section of the PLINK website, glist-hg18) and the file
pathway.txt is a file of gene names forming the pathway to be
tested for enrichment and the CNV data are in the files
mycnv.cnv, mycnv.cnv.map and mycnv.fam (see website CNV
page for details), then one can ask whether a) genes are enriched
for CNVs, b) a subset of genes are enriched, relative to the whole
genome, c) a subset of genes are enriched, relative to all genes. The
latter form of the enrichment test might be desirable, for example,
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to determine whether any enrichment is general to all genes, or
specific to a subset of genes.
a) Enrichment of genic CNVs
./plink ––cfile mycnv
––cnv-count genes.dat
––cnv-enrichment-test
b) Enrichment of pathway genes CNVs, relative to all
CNVs
./plink ––cfile mycnv
––cnv-count genes.dat
––cnv-subset pathway.txt
––cnv-enrichment-test
c) Enrichment of pathway genes CNVs, relative to all
genic CNVs
./plink ––cfile mycnv
––cnv-intersect genes.dat
––cnv-write my-genic-cnv
./plink ––cfile my-genic-cnv
––cnv-count genes.dat
––cnv-subset pathway.txt
––cnv-enrichment-test
The usual modifiers (to define intersection differently, allow for a
certain kb border around each gene, filter on CNV size, type or
frequency, etc) are all available. Under all circumstances, 2-sided
asymptotic p-values are returned. Alternatively, permutation testing
can be applied and 1-sided empirical p-values are returned (positive
enrichment in cases, based on estimated regression coefficient).
For additional information consult the PLINK website (http://
pngu.mgh.harvard.edu/purcell/plink/), the resources subsection
(gene list) (http://pngu.mgh.harvard.edu/purcell/plink/res.shtml),
or the CNV file format subsection (http://pngu.mgh.harvard.edu/
purcell/plink/cnv.shtml).
Supporting Information
Figure S1 Features predicting whether a gene overlaps a CNV
in the meta-controls. A. Here we plot the distribution of the genes
that are not deleted (n=14,027, blue) and the genes that are
deleted (n=538, red) separately for the meta-controls. Deleted
genes are larger with a median of 66 kb compared to genes not
deleted with a median of 27 kb. Medians and inter-quartile ranges
are indicated with the boxes, while the range indicates the 2.5 to
97.5 percentiles for both distributions. B. We plot the fraction
intrinic fraction score as a function of gene size. Larger genes tend
to have potentially greater proportions of events that could be fully
intronic. Red points indicate deleted genes while blue point
indicate the remainder. C. Here we plot the local gene density, i.e.,
the number of other nearby genes overlapped by a CNV as a
function of gene size. Events overlapping large genes tend not to
overlap other nearby genes. Red points indicate deleted genes
while blue points indicate the remainder.
Found at: doi:10.1371/journal.pgen.1001097.s001 (1.85 MB TIF)
Table S1 Gene size of brain genes highlighted in three CNV-
association studies. Here we list affected genes within gene sets
highlighted in three neuropsychiatric disease studies. In the first
column we list the study, in the next two columns we list the
functional gene sets and their source. In the fourth and fifth
column we list the genes, and their sizes. In the final column we list
the mean size. Many of the genes highlighted in all three studies
are very large genes. *For the Walsh et al. study, these genes were
compiled from multiple brain function gene sets.
Found at: doi:10.1371/journal.pgen.1001097.s002 (0.09 MB
DOC)
Table S2 Simulated distribution of CNV rate and size in cases
and controls. We tested different statistical models as outlined in
Materials and Methods (M0–M4) for false positive associations
under each of five extreme scenarios (S0–S4) outlined in the above
table. For a single hypothetical chromosome, 250Mb in length, we
placed 2000 evenly-spaced, non-overlapping genes. Every fifth
gene was designated as a ‘‘brain gene’’; brain genes were set to be
considerably larger than other genes (50kb versus 10kb). In all
scenarios we simulated CNV data for 2000 cases and 2000
controls, specifying the mean CNV size was either 60kb or 100kb
(range 10kb to 150kb, standard deviation 30kb) and CNV rate per
individual. Under the first scenario, S0, there were no differences
between cases and controls in the rate and size of CNVs: we
therefore expected all methods to give appropriate type I error
rates here. Under S1, the rate of CNVs was higher in cases. Under
S2, the average CNV size was smaller in cases. Under S3, cases
had a greater number, and larger, CNVs than controls. Under S4,
cases had a greater number, but smaller, CNVs than controls.
Found at: doi:10.1371/journal.pgen.1001097.s003 (0.04 MB
DOC)
Table S3 Collections examined in this study. Our study
examined affected and unaffected individuals from the ISC,
Walsh et al., and Zhang et al.. We also used unaffected populations
from four separate studies (meta-controls). For each study we list
the number of samples, the genotyping technology used to identify
CNVs (Representational Oligonucleotide Microarray Analysis
(ROMA), Affymetrix 5.0 (5.0) or Affymetrix 6.0 (6.0)), the number
of observed events, how we defined a ‘rare’ event, their size, and
the number of genes affected by those events.
Found at: doi:10.1371/journal.pgen.1001097.s004 (0.06 MB
DOC)
Table S4 Deletion in meta-controls events called in four
separate populations. Meta-control rare deletion events were
called based on Affymetrix 6.0 arrays. For each of the four
collections we list the number of samples, the number of rare
deletions.20 kb and the ratio of deletions to samples, the number
of rare deletions .100 kb and the ratio of deletions to samples,
and finally the median event size.
Found at: doi:10.1371/journal.pgen.1001097.s005 (0.04 MB
DOC)
Table S5 Gene ontology codes with the largest genes are
enriched in meta-controls. Here we list 13 GO codes with an
average gene length .200 kb and their descriptions in the first
four columns. In the next three columns we list the number of
genes for each code overlapping rare deletions in meta-controls,
the odds ratio, and the statistical significance. All enrichment
analyses p-values are calculated with Fisher’s exact test; enrich-
ment is calculated for both disrupted and deleted genes. In the
final three columns we list the number of genes disrupted by rare
deletions in meta-controls, the odds ratio, and the statistical
significance.
Found at: doi:10.1371/journal.pgen.1001097.s006 (0.06 MB
DOC)
Table S6 CNVprop scores of genes.
Found at: doi:10.1371/journal.pgen.1001097.s007 (0.66 MB
TXT)
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